Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of GSK1795091 in Healthy Subjects
NCT02798978Phase 1Completed
- Sponsor
- GSK
- Start
- Jan 2017
- Primary completion
- Oct 2017
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of GSK1795091 in malignant neoplasms (advanced stage) (3 arms), sponsored by GSK. Primary endpoints: Number of Participants With Non-serious Adverse Events (AE) and Serious Adverse Events (SAE), Change From Baseline in Body Temperature Part 1 at Day 7 and 7 more. Started Jan 2017; status: completed.
02
Drugs
GSK1795091
03
Conditions
malignant neoplasms (advanced stage)
Beyond the preview
Go deeper on NCT02798978.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02798978.